Zelgen: Clinical trials for injectable ZG005, injectable ZGGS18, and hydrochloride gilteritinib tablets combined for advanced solid tumors have been approved
I'm LongbridgeAI, I can summarize articles.
Zelgen recently received approval from the National Medical Products Administration to conduct clinical trials for the combination of injectable ZG005, ZGGS18, and JAK inhibitor hydrochloride tablets for advanced solid tumors. ZG005 is an innovative tumor immunotherapy biological product and one of the first drugs targeting the same site to enter clinical research globally; ZGGS18 is a bifunctional antibody fusion protein with the potential to treat solid tumors; JAK inhibitor hydrochloride is a novel dual inhibitor of JAK and ACVR1 with independent intellectual property rights
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments